



Nyrada Annual General Meeting Results

Sydney, 19 November 2021: Nyrada Inc (ASX: NYR), a preclinical stage, drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases announces the results of today's Annual General Meeting.

The results are set out in the attached document, in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act.

All resolutions were passed and decided by way of a poll.

- ENDS -

Authorised by John Moore, Non-Executive Chairman, on behalf of the Board.

About Nyrada Inc

Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.

www.nyrada.com

Investor & Corporate Enquiries:

Laura Vize
Investor Relations Manager
T: 0417 026 056
E: info@nyrada.com

Company Secretary:

David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries:

Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com



Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.

Disclosure of Proxy Votes

Nyrada Inc

Annual General Meeting (AGM) 2021

Friday, 19 November 2021



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Election of Mr. John Moore as Director	P	55,420,952	55,400,952 99.96%	0 0.00%	25,734	20,000 0.04%	55,538,627 100.00%	0 0.00%	25,734
2 Re-election of Mr. Christopher Cox as Director	P	55,446,686	55,426,686 99.96%	0 0.00%	0	20,000 0.04%	55,564,361 100.00%	0 0.00%	0
3 Re-election of Dr. Ian Dixon as Director	P	55,446,686	55,426,686 99.96%	0 0.00%	0	20,000 0.04%	55,564,361 100.00%	0 0.00%	0
4 Re-election of Mr. Marcus Frampton as Director	P	55,446,686	55,426,686 99.96%	0 0.00%	0	20,000 0.04%	55,564,361 100.00%	0 0.00%	0
5 Re-election of Mr. Peter Marks as Director	P	55,196,686	55,176,686 99.96%	0 0.00%	250,000	20,000 0.04%	55,314,361 100.00%	0 0.00%	250,000
6 Re-election of Dr. Ruediger Weseloh as Director	P	55,446,686	55,426,686 99.96%	0 0.00%	0	20,000 0.04%	55,564,361 100.00%	0 0.00%	0
7 ASX Listing Rule 7.1A Approval of Future Issue of Securities	P	55,392,697	55,330,463 99.89%	42,234 0.08%	53,989	20,000 0.04%	55,468,138 99.92%	42,234 0.08%	53,989

